P16‐85: Differences in the therapeutic effects of corticosteroid and immunosuppressants between the two subtypes of systemic sclerosis‐associated interstitial lung disease
Аннотация:Background and Aims: The treatment appropriate for the subtypes of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is yet to be known.Our aim was to investigate the relationship between changes in pulmonary function and the types of medication for the subtypes of SSc-ILD.Methods: We retrospectively collected the data of 29 patients diagnosed with SSc-ILD at our hospital between April 2011 and September 2020.We analyzed patient characteristics, SSc-ILD subtypes (diffuse cutaneous systemic sclerosis-ILD, dcSSc-ILD and limited cutaneous systemic sclerosis-ILD, lcSSc-ILD), antibodies, medications, and pulmonary function in SSc-ILD patients.Results: Median age at diagnosis of SSc-ILD was 56.5 years.Eight patients were male.Fourteen patients were diagnosed with ds-SSc-ILD.The decline in forced vital capacity (FVC) was 103 mL/year among all SSc-ILD patients.No significant difference in the decline in FVC between dcSSc-ILD and lcSSc-ILD was found.FVC decline tended to be lower in patients who received corticosteroid with calcineurin inhibitors than in patients who received corticosteroid without calcineurin inhibitors (corticosteroid only or corticosteroid with cyclophosphamide/mycophenolate mofetil) in total patients.In lcSSc-ILD patients, FVC change tended to be lower in patients who received corticosteroid with calcineurin inhibitors than in patients who received corticosteroid without calcineurin inhibitors.In contrast, there was no significant difference in FVC decline between the presence and absence of calcineurin inhibitors in corticosteroid therapy for dcSSc-ILD.Conclusions: Corticosteroid with calcineurin inhibitors may be effective in lcSSc-ILD.
